A Randomized Phase II Trial of Perioperative Chemoimmunotherapy Verses Perioperative Chemoimmunotherapy Plus Preoperative Chemoradiation for Locally Advanced Gastric (G) or ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2021-2026

ABSTRACT

NeoRacing is a randomized phase II trial carried out at Fudan University Shanghai Cancer Center (FUSCC) in China. The study can be divided into the screening stage, treatment stage and follow-up stage. The enrolled patients will receive perioperative SOX chemotherapy, PD-1 antibody (sintilimab) and radical surgery, with or without preoperative CRT. The patients were randomized by stratified permutated block randomization on a web-based system . The status of peritoneal cytological examination (CY0 vs. CY1) was the stratification factor. The study protocol was approved by the Ethics Committee of FUSCC. All patients provided written informed consent before recruitment. Monitoring will be carried out in this tri Detailed Description Perioperative chemotherapy (ChT) and preoperative chemoradiation (CRT) are both the standard treatments for locally advanced gastric cancer (LAGC). CRT can achieve a higher pathological complete regression (pCR) rate, but whether this higher pCR rate can be transformed into a long-term survival benefit remains inconclusive. Therefore, relevant studies are in progress. On the other hand, immunotherapy has been established for the first-line treatment of advanced gastric cancer (AGC) and has been widely explored in the perioperative setting. The combination of chemotherapy/radiotherapy and immunotherapy may have a synergistic effect, which will lead to a better antitumor effect. The preliminary reports of ongoing studies show promising results, including a further improved pCR rate. However, the preferred treatment combination for LAGC is still not established. To solve this problem, we are carrying out this randomized phase II trial, which aims to evaluate the efficacy and safety of perioperative chemotherapy plus the use of PD-1 antibodies with or without preoperative chemoradiation for LAGC.Perioperative chemotherapy (ChT) and preoperative chemoradiation (CRT) are both the standard treatments for locally advanced gastric cancer (LAGC). CRT can achieve a higher pathological complete regression (pCR) rate, but whether this higher pCR rate can be transformed into a long-term survival benefit remains inconclusive. Therefore, relevant studies are in progress. On the other hand, immunotherapy has been established for the first-line treatment of advanced gastric cancer (AGC) and has been widely explored in the perioperative setting. The combination of chemotherapy/radiotherapy and immunotherapy may have a synergistic effect, which will lead to a better antitumor effect. The preliminary reports of ongoing studies show promising results, including a further improved pCR rate. However, the preferred treatment combination for LAGC is still not established. To solve this problem, we are carrying out this randomized phase II trial, which aims to evaluate the efficacy and safety of perioperative chemotherapy plus the use of PD-1 antibodies with or without preoperative chemoradiation for LAGC.The results of the NeoRacing study will provide important information concerning the application of PD-1 antibodies in LAGC patients during the preoperative setting. Meanwhile, the two treatment protocols will be compared in terms of efficacy and safety. More... »

URL

https://clinicaltrials.gov/show/NCT05161572

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "NeoRacing is a randomized phase II trial carried out at Fudan University Shanghai Cancer Center (FUSCC) in China. The study can be divided into the screening stage, treatment stage and follow-up stage. The enrolled patients will receive perioperative SOX chemotherapy, PD-1 antibody (sintilimab) and radical surgery, with or without preoperative CRT. The patients were randomized by stratified permutated block randomization on a web-based system . The status of peritoneal cytological examination (CY0 vs. CY1) was the stratification factor. The study protocol was approved by the Ethics Committee of FUSCC. All patients provided written informed consent before recruitment. Monitoring will be carried out in this tri\n\nDetailed Description\nPerioperative chemotherapy (ChT) and preoperative chemoradiation (CRT) are both the standard treatments for locally advanced gastric cancer (LAGC). CRT can achieve a higher pathological complete regression (pCR) rate, but whether this higher pCR rate can be transformed into a long-term survival benefit remains inconclusive. Therefore, relevant studies are in progress. On the other hand, immunotherapy has been established for the first-line treatment of advanced gastric cancer (AGC) and has been widely explored in the perioperative setting. The combination of chemotherapy/radiotherapy and immunotherapy may have a synergistic effect, which will lead to a better antitumor effect. The preliminary reports of ongoing studies show promising results, including a further improved pCR rate. However, the preferred treatment combination for LAGC is still not established. To solve this problem, we are carrying out this randomized phase II trial, which aims to evaluate the efficacy and safety of perioperative chemotherapy plus the use of PD-1 antibodies with or without preoperative chemoradiation for LAGC.Perioperative chemotherapy (ChT) and preoperative chemoradiation (CRT) are both the standard treatments for locally advanced gastric cancer (LAGC). CRT can achieve a higher pathological complete regression (pCR) rate, but whether this higher pCR rate can be transformed into a long-term survival benefit remains inconclusive. Therefore, relevant studies are in progress. On the other hand, immunotherapy has been established for the first-line treatment of advanced gastric cancer (AGC) and has been widely explored in the perioperative setting. The combination of chemotherapy/radiotherapy and immunotherapy may have a synergistic effect, which will lead to a better antitumor effect. The preliminary reports of ongoing studies show promising results, including a further improved pCR rate. However, the preferred treatment combination for LAGC is still not established. To solve this problem, we are carrying out this randomized phase II trial, which aims to evaluate the efficacy and safety of perioperative chemotherapy plus the use of PD-1 antibodies with or without preoperative chemoradiation for LAGC.The results of the NeoRacing study will provide important information concerning the application of PD-1 antibodies in LAGC patients during the preoperative setting. Meanwhile, the two treatment protocols will be compared in terms of efficacy and safety.", 
    "endDate": "2026-09", 
    "id": "sg:clinicaltrial.NCT05161572", 
    "keywords": [
      "Fudan University Shanghai Cancer Center", 
      "advanced gastric cancer", 
      "phase II trial", 
      "PD-1 antibody", 
      "long-term survival benefit", 
      "randomized phase II trial", 
      "preoperative chemoradiation", 
      "chemotherapy/radiotherapy", 
      "first-line treatment", 
      "complete regression rate", 
      "perioperative chemotherapy", 
      "II trial", 
      "gastric cancer", 
      "better antitumor effect", 
      "survival benefit", 
      "standard treatment", 
      "perioperative setting", 
      "antitumor effects", 
      "relevant studies", 
      "Shanghai Cancer Center", 
      "gastroesophageal junction adenocarcinoma", 
      "preliminary report", 
      "terms of efficacy", 
      "ongoing studies", 
      "SOX chemotherapy", 
      "radical surgery", 
      "advanced gastric", 
      "junction adenocarcinoma", 
      "preoperative setting", 
      "Cancer Center", 
      "study protocol", 
      "LAGC patients", 
      "chemoradiation", 
      "treatment protocol", 
      "block randomization", 
      "stratification factors", 
      "chemotherapy", 
      "immunotherapy", 
      "cytological examination", 
      "patients", 
      "informed consent", 
      "regression rate", 
      "cancer", 
      "Ethics Committee", 
      "LAGC", 
      "trials", 
      "antibodies", 
      "efficacy", 
      "treatment", 
      "radiotherapy", 
      "promising results", 
      "treatment combinations", 
      "safety", 
      "synergistic effect", 
      "report", 
      "setting", 
      "chemoimmunotherapy", 
      "surgery", 
      "adenocarcinoma", 
      "gastric", 
      "study", 
      "screening stage", 
      "treatment stage", 
      "rate", 
      "effect", 
      "randomization", 
      "consent", 
      "examination", 
      "protocol", 
      "benefits", 
      "status", 
      "combination", 
      "stage", 
      "important information", 
      "recruitment", 
      "use", 
      "factors", 
      "Committee", 
      "web-based system", 
      "center", 
      "results", 
      "hand", 
      "progress", 
      "monitoring", 
      "detailed description", 
      "information", 
      "problem", 
      "China", 
      "system", 
      "terms", 
      "description", 
      "applications"
    ], 
    "name": "A Randomized Phase II Trial of Perioperative Chemoimmunotherapy Verses Perioperative Chemoimmunotherapy Plus Preoperative Chemoradiation for Locally Advanced Gastric (G) or Gastroesophageal Junction (GEJ) Adenocarcinoma", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT05161572"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2022-09-02T16:19", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/clinical_trial/clinical_trial_1.jsonl", 
    "startDate": "2021-09", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1007/s10120-016-0622-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005167644", 
          "https://doi.org/10.1007/s10120-016-0622-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10120-011-0041-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016436945", 
          "https://doi.org/10.1007/s10120-011-0041-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12885-019-5728-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1117295752", 
          "https://doi.org/10.1186/s12885-019-5728-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12885-018-4770-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106903985", 
          "https://doi.org/10.1186/s12885-018-4770-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1245/s10434-017-5830-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084256628", 
          "https://doi.org/10.1245/s10434-017-5830-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12885-015-1529-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046192944", 
          "https://doi.org/10.1186/s12885-015-1529-x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT05161572"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT05161572'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT05161572'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT05161572'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT05161572'


 

This table displays all metadata directly associated to this object as RDF triples.

136 TRIPLES      15 PREDICATES      113 URIs      101 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT05161572 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:description NeoRacing is a randomized phase II trial carried out at Fudan University Shanghai Cancer Center (FUSCC) in China. The study can be divided into the screening stage, treatment stage and follow-up stage. The enrolled patients will receive perioperative SOX chemotherapy, PD-1 antibody (sintilimab) and radical surgery, with or without preoperative CRT. The patients were randomized by stratified permutated block randomization on a web-based system . The status of peritoneal cytological examination (CY0 vs. CY1) was the stratification factor. The study protocol was approved by the Ethics Committee of FUSCC. All patients provided written informed consent before recruitment. Monitoring will be carried out in this tri Detailed Description Perioperative chemotherapy (ChT) and preoperative chemoradiation (CRT) are both the standard treatments for locally advanced gastric cancer (LAGC). CRT can achieve a higher pathological complete regression (pCR) rate, but whether this higher pCR rate can be transformed into a long-term survival benefit remains inconclusive. Therefore, relevant studies are in progress. On the other hand, immunotherapy has been established for the first-line treatment of advanced gastric cancer (AGC) and has been widely explored in the perioperative setting. The combination of chemotherapy/radiotherapy and immunotherapy may have a synergistic effect, which will lead to a better antitumor effect. The preliminary reports of ongoing studies show promising results, including a further improved pCR rate. However, the preferred treatment combination for LAGC is still not established. To solve this problem, we are carrying out this randomized phase II trial, which aims to evaluate the efficacy and safety of perioperative chemotherapy plus the use of PD-1 antibodies with or without preoperative chemoradiation for LAGC.Perioperative chemotherapy (ChT) and preoperative chemoradiation (CRT) are both the standard treatments for locally advanced gastric cancer (LAGC). CRT can achieve a higher pathological complete regression (pCR) rate, but whether this higher pCR rate can be transformed into a long-term survival benefit remains inconclusive. Therefore, relevant studies are in progress. On the other hand, immunotherapy has been established for the first-line treatment of advanced gastric cancer (AGC) and has been widely explored in the perioperative setting. The combination of chemotherapy/radiotherapy and immunotherapy may have a synergistic effect, which will lead to a better antitumor effect. The preliminary reports of ongoing studies show promising results, including a further improved pCR rate. However, the preferred treatment combination for LAGC is still not established. To solve this problem, we are carrying out this randomized phase II trial, which aims to evaluate the efficacy and safety of perioperative chemotherapy plus the use of PD-1 antibodies with or without preoperative chemoradiation for LAGC.The results of the NeoRacing study will provide important information concerning the application of PD-1 antibodies in LAGC patients during the preoperative setting. Meanwhile, the two treatment protocols will be compared in terms of efficacy and safety.
4 schema:endDate 2026-09
5 schema:keywords Cancer Center
6 China
7 Committee
8 Ethics Committee
9 Fudan University Shanghai Cancer Center
10 II trial
11 LAGC
12 LAGC patients
13 PD-1 antibody
14 SOX chemotherapy
15 Shanghai Cancer Center
16 adenocarcinoma
17 advanced gastric
18 advanced gastric cancer
19 antibodies
20 antitumor effects
21 applications
22 benefits
23 better antitumor effect
24 block randomization
25 cancer
26 center
27 chemoimmunotherapy
28 chemoradiation
29 chemotherapy
30 chemotherapy/radiotherapy
31 combination
32 complete regression rate
33 consent
34 cytological examination
35 description
36 detailed description
37 effect
38 efficacy
39 examination
40 factors
41 first-line treatment
42 gastric
43 gastric cancer
44 gastroesophageal junction adenocarcinoma
45 hand
46 immunotherapy
47 important information
48 information
49 informed consent
50 junction adenocarcinoma
51 long-term survival benefit
52 monitoring
53 ongoing studies
54 patients
55 perioperative chemotherapy
56 perioperative setting
57 phase II trial
58 preliminary report
59 preoperative chemoradiation
60 preoperative setting
61 problem
62 progress
63 promising results
64 protocol
65 radical surgery
66 radiotherapy
67 randomization
68 randomized phase II trial
69 rate
70 recruitment
71 regression rate
72 relevant studies
73 report
74 results
75 safety
76 screening stage
77 setting
78 stage
79 standard treatment
80 status
81 stratification factors
82 study
83 study protocol
84 surgery
85 survival benefit
86 synergistic effect
87 system
88 terms
89 terms of efficacy
90 treatment
91 treatment combinations
92 treatment protocol
93 treatment stage
94 trials
95 use
96 web-based system
97 schema:name A Randomized Phase II Trial of Perioperative Chemoimmunotherapy Verses Perioperative Chemoimmunotherapy Plus Preoperative Chemoradiation for Locally Advanced Gastric (G) or Gastroesophageal Junction (GEJ) Adenocarcinoma
98 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT05161572
99 schema:sdDatePublished 2022-09-02T16:19
100 schema:sdLicense https://scigraph.springernature.com/explorer/license/
101 schema:sdPublisher N2d160834fd3246bbafb08320be139d04
102 schema:startDate 2021-09
103 schema:subjectOf sg:pub.10.1007/s10120-011-0041-5
104 sg:pub.10.1007/s10120-016-0622-4
105 sg:pub.10.1186/s12885-015-1529-x
106 sg:pub.10.1186/s12885-018-4770-2
107 sg:pub.10.1186/s12885-019-5728-8
108 sg:pub.10.1245/s10434-017-5830-6
109 schema:url https://clinicaltrials.gov/show/NCT05161572
110 sgo:license sg:explorer/license/
111 sgo:sdDataset clinical_trials
112 rdf:type schema:MedicalStudy
113 N2d160834fd3246bbafb08320be139d04 schema:name Springer Nature - SN SciGraph project
114 rdf:type schema:Organization
115 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
116 rdf:type schema:DefinedTerm
117 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
118 rdf:type schema:DefinedTerm
119 sg:pub.10.1007/s10120-011-0041-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016436945
120 https://doi.org/10.1007/s10120-011-0041-5
121 rdf:type schema:CreativeWork
122 sg:pub.10.1007/s10120-016-0622-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005167644
123 https://doi.org/10.1007/s10120-016-0622-4
124 rdf:type schema:CreativeWork
125 sg:pub.10.1186/s12885-015-1529-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1046192944
126 https://doi.org/10.1186/s12885-015-1529-x
127 rdf:type schema:CreativeWork
128 sg:pub.10.1186/s12885-018-4770-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106903985
129 https://doi.org/10.1186/s12885-018-4770-2
130 rdf:type schema:CreativeWork
131 sg:pub.10.1186/s12885-019-5728-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1117295752
132 https://doi.org/10.1186/s12885-019-5728-8
133 rdf:type schema:CreativeWork
134 sg:pub.10.1245/s10434-017-5830-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084256628
135 https://doi.org/10.1245/s10434-017-5830-6
136 rdf:type schema:CreativeWork
 




Preview window. Press ESC to close (or click here)


...